Prevalence of hepatitis B virus DNA polymerase mutations in treatment‐naïve patients with chronic hepatitis B
Authors:
- 2 November 2009
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 30 (11-12) , 1150-1158
Abstract
Summary: Background One of the most important factors in treatment failure using nucleos(t)ide analogues in chronic hepatitis B is anti‐viral resistance. Primary drug resistance refers to amino acid changes in the hepatitis B virus polymerase/reverse transcriptase (rt) that result in reduced susceptibility to anti‐viral agents. Pre‐existing drug resistance mutations may occur in untreated patients and may affect their treatment outcomes.Aim To determine the prevalence of hepatitis B DNA polymerase mutations in treatment‐naïve patients.Methods We used a direct PCR sequencing test to detect DNA polymerase mutations in 472 consecutive treatment‐naïve patients at two community gastroenterology clinics in Northern California.Results A majority of patients were Asians (>95%), had either genotype B or C (95%) and had no evidence of cirrhosis or liver cancer (94%). Mean age was 45 ± 13 and mean hepatitis B virus DNA was 5.3 ± 1.8 log10 IU/mL. Most patients did not have any detectable mutations (82.4%). Some (16.7%) had mutations of unknown clinical significance (rtV207M/L/I) and only 4 patients had rtA181A/S, rtA194S or M250I.Conclusions No rtM204V/I or rtN236T mutations were observed in our study. Less than 1% of our patients had mutations that can be associated with primary resistance to existing anti‐viral therapies for hepatitis B virus.Keywords
This publication has 20 references indexed in Scilit:
- Ultra‐Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse‐Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI‐Naive PatientsThe Journal of Infectious Diseases, 2009
- Entecavir therapy for lamivudine‐refractory chronic hepatitis BHepatology, 2008
- Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failureHepatology International, 2008
- YMDD motif variants in inactive hepatitis B carriers detected by Inno‐Lipa HBV DR assayJournal of Gastroenterology and Hepatology, 2006
- Sensitive Line Probe Assay That Simultaneously Detects Mutations Conveying Resistance to Lamivudine and AdefovirJournal of Clinical Microbiology, 2006
- Natural History of Chronic Hepatitis B Virus Infection: What We Knew in 1981 and What We Know in 2005Hepatology, 2006
- Dynamics of Hepatitis B Virus Resistance to LamivudineJournal of Virology, 2006
- Epidemiology and Natural History of Hepatitis BSeminars in Liver Disease, 2005
- Four years of lamivudine treatment in Chinese patients with chronic hepatitis BJournal of Gastroenterology and Hepatology, 2004
- Rapid and Sensitive Assays for Determination of Hepatitis B Virus (HBV) Genotypes and Detection of HBV Precore and Core Promoter VariantsJournal of Clinical Microbiology, 2003